Adverse	adverse	O	O
interaction	interaction	O	O
between	between	O	O
beta-adrenergic	beta-adrenergic	O	O
blocking	blocking	O	O
drugs	drugs	O	O
and	and	O	O
verapamil	verapamil	S_chemical	O
--	--	O	O
report	report	O	O
of	of	O	O
three	three	O	O
cases	cases	O	O
.	.	O	O

Three	three	O	O
patients	patients	O	O
with	with	O	O
ischaemic	ischaemic	O	O
heart	heart	O	B_disease
disease	disease	O	I_disease
developed	developed	O	O
profound	profound	O	O
cardiac	cardiac	O	B_disease
failure	failure	O	I_disease
,	,	O	O
hypotension	hypotension	O	S_disease
and	and	O	O
bradycardia	bradycardia	O	S_disease
during	during	O	O
combined	combined	O	O
therapy	therapy	O	O
with	with	O	O
verapamil	verapamil	S_chemical	O
and	and	O	O
beta-adrenergic	beta-adrenergic	O	O
blocking	blocking	O	O
drugs	drugs	O	O
.	.	O	O

This	this	O	O
clinical	clinical	O	O
picture	picture	O	O
resolved	resolved	O	O
completely	completely	O	O
with	with	O	O
cessation	cessation	O	O
of	of	O	O
the	the	O	O
combined	combined	O	O
therapy	therapy	O	O
.	.	O	O

Baseline	baseline	O	O
left	left	O	O
ventricular	ventricular	O	O
function	function	O	O
,	,	O	O
assessed	assessed	O	O
by	by	O	O
cardiac	cardiac	O	O
catheterisation	catheterisation	O	O
or	or	O	O
nuclear	nuclear	O	O
angiography	angiography	O	O
,	,	O	O
was	was	O	O
normal	normal	O	O
in	in	O	O
two	two	O	O
patients	patients	O	O
and	and	O	O
only	only	O	O
mildly	mildly	O	O
reduced	reduced	O	O
in	in	O	O
the	the	O	O
other	other	O	O
.	.	O	O

Simultaneously	simultaneously	O	O
administration	administration	O	O
of	of	O	O
beta-adrenergic	beta-adrenergic	O	O
blocking	blocking	O	O
drugs	drugs	O	O
and	and	O	O
verapamil	verapamil	S_chemical	O
may	may	O	O
result	result	O	O
in	in	O	O
profound	profound	O	O
adverse	adverse	O	O
interactions	interactions	O	O
and	and	O	O
should	should	O	O
only	only	O	O
be	be	O	O
administered	administered	O	O
with	with	O	O
great	great	O	O
caution	caution	O	O
.	.	O	O

